INMB | INmune Bio, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	5.96 - 6.34
52 Week Range	4.78 - 14.74
Beta	1.62
Implied Volatility	146.76%
IV Rank	46.06%
Day's Volume	182,549
Average Volume	249,837
Shares Outstanding	22,172,500
Market Cap	138,578,125
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-02-04

Valuation
Profitability
Growth
Health
P/E Ratio	-2.87
Forward P/E Ratio	N/A
EPS	-2.18
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	11
Country	USA
Website	INMB

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

INMB's peers: ADMA, ALT, ANIX, AVXL, BCRX, CUE, INAB, TFFP, ANEB, ABCM, ANTX, PYPD, AVTE, ELYM, DBTX, SAVA, BIVI, CGTX, TCRX, DRMA, SNPX

*Chart delayed

Analyzing fundamentals for INMB we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see INMB Fundamentals page.

Watching at INMB technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on INMB Technicals page.